Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418691 · ClinicalTrials.gov registry record · Phase 3
Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT00418691: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00418691 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00418691, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
Primary Objective: * To assess the efficacy of immediate release methylphenidate, sustained release methylphenidate, and the novel vigilance enhancing drug modafinil for the improvement of cognitive functioning in patients with brain tumors.
Interventions
- DRUG Modafinil
- DRUG IR Methylphenidate
- DRUG SR Methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2004-02 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00418691
The ClinicalTrials.gov registry entry for NCT00418691 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Modafinil is the first listed.
NCT00418691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00418691 about?
NCT00418691 is a clinical study titled "Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning". Primary Objective: * To assess the efficacy of immediate release methylphenidate, sustained release methylphenidate, and the novel vigilance enhancing drug modafinil for the improvement of cognitive functioning in patients with brain tumors.
What is the current status of trial NCT00418691?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2004-02. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00418691?
The interventions under investigation include: Modafinil (DRUG), IR Methylphenidate (DRUG), SR Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00418691?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.